| Literature DB >> 35522610 |
Lalitha Maniam1, Kumutha Malar Vellasamy1, Hassan Mahmood Jindal1, Vallikannu Narayanan2, Mahmoud Danaee3, Jamuna Vadivelu1, Vinod Pallath4.
Abstract
Asymptomatic bacteriuria (ASB) caused by Escherichia coli (E. coli) is a significant condition associated with pregnancy and is considered as prognostic for the development of symptomatic urinary tract infection (UTI). However, treating all ASB increases the use of antibiotics and leads to the development of multidrug resistance (MDR). Therefore, this study aimed to identify the distribution of UPEC associated virulence genes and antibiotic susceptibility among phylogroups of E. coli isolated from ASB in pregnancy. Moreover, the gene expression of selected virulence genes was also compared among two E. coli isolates (with different pathogenic potential) to determine its pathogenicity. One hundred and sixty E. coli isolates from midstream urine samples of pregnant women with ASB were subjected to PCR-based detection for its phylogroups and virulence genes. The antibiotic susceptibility of isolated strains was determined by the disc diffusion method. Expression of the virulence genes were determined through microarray analysis and quantitative Real-Time PCR. The prevalence of ASB in this study was 16.1%. Within ASB isolates, the occurrence of phylogroup B2 was the highest, and isolates from this group harboured most of the virulence genes studied. Overall, the most identified virulence genes among all phylogroups in descending order were fimH, chuA, kpsMTII, usp, fyuA, hlyA, iroN, cnf, papC, sfa, ompT, and sat. In this study, higher resistance to antibiotics was observed for ampicillin (77.5%), amoxicillin-clavulanate (54.4%), trimethoprim-sulfamethoxazole (46.9%) and amikacin (43.8%) compared to the other tested antibiotics and 51.9% of the tested isolates were MDR. Furthermore, hierarchical clustering and gene expression analysis demonstrated extreme polarization of pathogenic potential of E. coli causing ASB in pregnancy necessitating the need for bacterial isolate focused approach towards treatment of ASB.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35522610 PMCID: PMC9075641 DOI: 10.1371/journal.pone.0267296
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Primer used for the phylogenotyping and E. coli identification (16s rRNA).
| PCR Reaction | Primer | Primer sequence | Amplicon size (bp) |
|---|---|---|---|
| Quadruplex |
| 288 | |
|
| |||
|
| 211 | ||
|
| |||
|
| 152 | ||
|
| |||
|
| 400 | ||
|
| |||
| Group C |
| 219 | |
|
| |||
| Group E |
| 301 | |
|
| |||
| Internal control |
| 489 | |
|
| |||
| 16s rRNA |
| 100 | |
|
|
List of Primers used in virulence genotyping.
| Virulence genes | Primer sequence | Amplicon size (bp) | Reference | |
|---|---|---|---|---|
|
| ||||
| P fimbriae |
|
| 328 | [ |
|
| ||||
| Type 1 fimbriae |
|
| 508 | [ |
|
| ||||
| S fimbriae |
|
| 410 | [ |
|
| ||||
|
| ||||
| Salmochelin receptor |
|
| 665 | [ |
|
| ||||
| Yersiniabactin receptor |
|
| 715 | [ |
|
| ||||
|
| ||||
| Alpha hemolysin |
|
| 1177 | [ |
|
| ||||
| Cytotoxic necrotising factor |
|
| 498 | [ |
|
| ||||
| Secreted autotransporter toxin |
|
| 393 | [ |
|
| ||||
| Uropathogen specific protein |
|
| 448 | [ |
|
| ||||
|
| ||||
| kpsMT group II capsule |
|
| 272 | [ |
|
| ||||
| Outer membrane protease T |
|
| 559 | [ |
|
| ||||
Distributions of virulence genes among ASB E. coli isolates.
| Virulence gene | A | B1 | B2 | C | D | E | F | Clade1 | NT | Total | p-value | X2 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 35 | n = 27 | n = 55 | n = 5 | n = 13 | n = 13 | n = 5 | n = 3 | n = 4 | n = 160 | |||
|
| ||||||||||||
|
| 27(77.1) | 24(88.9) | 38(69.1) | 4(80.0) | 9(69.2) | 9(69.2) | 5(100.0) | 2(66.7) | 3(75.0) | 121 (75.6) | 0.634 | 6.266 |
|
| 3(8.6) | 2(7.4) | 19 (34.5) | 2(40.0) | 0 | 1(7.7) | 0 | 0 | 0 | 27(16.9) | 0.005 | 23.451 |
|
| 5(14.3) | 3(11.1) | 16(29.1) | 3(60.0) | 3(23.1) | 1(7.7) | 1(20.0) | 0 | 1(25.0) | 33(20.6) | 0.156 | 11.698 |
|
| ||||||||||||
|
| 5(14.3) | 5(18.5) | 23 (41.8) | 0 | 3 (23.1) | 1(7.7) | 0 | 1(33.3) | 1(25.0) | 39(24.4) | 0.030 | 16.843 |
|
| 8 (22.9) | 4 (14.8) | 25 (45.5) | 2 (40.0) | 3 (23.1) | 3 (23.1) | 3 (60.0) | 1 (33.3) | 2 (50.0) | 51 (31.9) | 0.100 | 13.109 |
|
| 0 | 0 | 55(100) | 0 | 13(100) | 13(100) | 5(100) | 0(0) | 2(50) | 88 (55.0) | 0.001 | 110.922 |
|
| ||||||||||||
|
| 4 (11.1) | 4(14.8) | 24 (43.6) | 0 | 0 | 2 (15.4) | 0 | 1 (33.3) | 1 (25.0) | 36 (22.5) | 0.002 | 24.737 |
|
| 6 (17.1) | 8 (29.6) | 25 (45.5) | 1 (20.0) | 2 (15.4) | 1 (7.7) | 1 (20.0) | 0 | 0 | 44 (27.5) | 0.024 | 17.290 |
|
| 4 (11.4) | 0 | 1 (1.8) | 2 (40.0) | 1 (7.7) | 2 (15.4) | 2 (40.0) | 0 | 0 | 12 (7.5) | 0.015 | 22.486 |
|
| 3 (8.6) | 2 (7.4) | 38 (69.1) | 1 (20.0) | 4 (30.8) | 3 (23.1) | 1 (20.0) | 0 | 3 (75.0) | 55 (34.4) | <0.001 | 54.643 |
|
| ||||||||||||
|
| 5 (14.3) | 2 (7.4)b | 36 (65.5) | 2 (40.0) | 5 (38.5) | 4 (30.8) | 4 (80.0) | 0 | 3 (4.9) | 61 (38.1) | <0.001 | 44.823 |
|
| 3 (8.6) | 3 (11.1) | 7 (12.7) | 1 (20.0) | 3 (23.1) | 5 (38.5) | 0 | 0 | 2 (50.0) | 24 (15.0) | 0.101 | 13.308 |
a,b,c Group with different alphabets are statistically different at 0.05 level based on pairwise comparison.
Summary of the gene expression profile of two selected ASB isolates.
|
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| EC114 (low pathogenic potential) | Conventional PCR (DNA) | - | - | - | - | - | - | - | - | - | - | - | - |
| Gene expression (RNA) | - | - | - | - | - | - | - | - | - | - | - | - | |
| EC095 (high pathogenic potential) | Conventional PCR (DNA) | + | - | + | + | + | + | + | + | - | + | + | + |
| Gene expression (RNA) | + | - | + | + | + | + | + | + | - | + | + | - | |
*Gene expression profiles obtained from microarray analysis.
**Gene expression profiles obtained from RT-PCR.
+ indicates the presence of expression.
- indicates the absence of expression.
Significant differentially expressed virulence genes among ASB EC095 (high pathogenic potential) strain compared to EC114 (low pathogenic potential) strain using microarray analysis.
| Gene | Regulation | Fold change | Description |
|---|---|---|---|
|
| Up | 4.0393 | major type 1 subunit fimbrin |
|
| Up | 3.3423 | recombinase involved in phase variation; regulator for fimA |
|
| Up | 5.3053 | periplasmic chaperone, required for type 1 fimbriae |
|
| Up | 3.1863 | export and assembly of type 1 fimbriae |
|
| Up | 4.7253 | recombinase involved in phase variation; regulator for fimA |
|
| Up | 2.7634 | fimbrial morphology |
|
| Up | 2.9985 | fimbrial morphology |
|
| Up | 5.4889 | minor fimbrial subunit, D-mannose specific adhesin |
|
| Up | 7.2923 | fimbrial protein |
|
| Up | 3.4937 | PapC protein |
|
| Up | 2.8650 | PapF protein |
|
| Up | 4.2843 | PapG protein |
|
| Up | 2.9173 | PapJ protein |
|
| Up | 4.7184 | PapK protein |
|
| Up | 6.3801 | PapX protein |
|
| Up | 5.1316 | Putative F1C and S fimbrial switch Regulatory |
|
| Up | 4.6443 | Putative glucosyltransferase |
|
| Up | 4.1750 | Ferric enterochelin esterase |
|
| Up | 5.0085 | IroE protein |
|
| Up | 5.2658 | Siderophore receptor IroN |
|
| Up | 3.2172 | Outer membrane heme/hemoglobin receptor |
|
| Up | 2.1689 | putative heme/hemoglobin transport protein |
|
| Up | 3.7738 | Putative Periplasmic binding protein |
|
| Up | 3.6617 | Putative permease of iron compound ABC transport |
|
| Up | 2.2960 | Putative oxygen-independent coproporphyrinogen III oxidase |
|
| Up | 2.1485 | Hypothetical protein |
|
| Up | 3.2964 | Hypothetical protein |
|
| Up | 5.0457 | Hemolysin B |
|
| Up | 4.8671 | Hemolysin C |
|
| Up | 5.3834 | Hemolysin D |
|
| Up | 2.0408 | outer membrane protein |
|
| Up | 2.2054 | outer membrane protein |
|
| Down | -2.7222 | response regulator |
|
| Up | 6.2844 | Protease VII precursor |
|
| Up | 1.7231 | Outer membrane protein W precursor |
|
| Up | 2.0198 | KpsC protein |
|
| Up | 3.6400 | KpsD protein |
|
| Up | 2.0873 | KpsE protein |
|
| Down | -1.2465 | orf, hypothetical protein |
|
| Down | -1.7622 | putative regulator |
|
| Up | 11.6176 | orf, hypothetical protein |
All the genes included in this table were with log2 fold change of greater than two or less than −2 and with adjusted p-value (Benjamini-Hochberg adjustment) of less than 0.05 which showed significant differential expression.
* Virulence genes of interest in this study.
Antibiotic resistance profile of E. coli among different phylogroups.
| Group A | Group B1 | Group B2 | Group C | Group D | Group E | Group F | Clade 1 | Unknown | Total | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 35 | n = 27 | n = 55 | n = 5 | n = 13 | n = 13 | n = 5 | n = 3 | n = 4 | n = 160 | ||
|
| |||||||||||
| Ampicillin | 26 (74.3) | 23 (85.2) | 43 (78.2) | 3 (60.0) | 11 (84.6) | 10 (76.9) | 2 (40.0) | 2 (66.7) | 4 (100.0) | 124 (77.5) | 0.454 |
|
| |||||||||||
| Amoxicillin-clavulanate | 16 (45.7) | 20 (74.1) | 24 (43.6) | 2 (40.0) | 8 (61.5) | 11 (84.6) | 2 (40.0) | 2 (66.7) | 2 (50.0) | 87 (54.4) | 0.083 |
| Ampicillin-Sulbactam | 12 (34.3) | 12 (44.4) | 14 (25.5) | 2 (40.0) | 5 (38.5) | 6 (46.2) | 0 | 1 (33.3) | 0 | 52 (32.5) | 0.357 |
|
| |||||||||||
| Piperacillin- Tazobactam | 11 (31.4) | 8 (29.6) | 12 (21.8) | 0 | 4 (30.8) | 7 (53.8) | 1 (20.0) | 1 (33.3) | 2 (50.0) | 46 (28.7) | 0.381 |
| Ceforoxime | 13 (37.1) | 11 (40.7) | 15 (27.3) | 0 | 7 (53.8) | 5 (38.5) | 1 (20.0) | 1 (33.3) | 1 (25.0) | 54 (33.8) | 0.496 |
| Cefotaxime | 10 (28.6) | 8 (29.6) | 14 (25.5) | 1 (20.0) | 2 (15.4) | 3 (23.1) | 1 (20.0) | 1 (33.3) | 2 (50.0) | 42 (26.3) | 0.958 |
| Cefepime | 9 (25.7) | 5 (18.5) | 8 (14.5) | 0 | 3 (23.1) | 5 (38.5) | 1 (20.0) | 0 | 0 | 31 (19.4) | 0.457 |
| Ceftriaxone | 10 (28.6) | 8 (29.6) | 9 (16.4) | 0 | 3 (23.1) | 3 (23.1) | 1 (20.0) | 1 (33.3) | 0 | 35 (21.9) | 0.689 |
|
| |||||||||||
| Cefoxitin | 8 (22.9) | 5 (18.5) | 6 (10.9) | 0 | 2 (15.4) | 3 (23.1) | 1 (20.0) | 0 | 0 | 25 (15.6) | 0.722 |
|
| |||||||||||
| Trimethprim -sulfamethoxazole | 20 (57.1) | 14 (51.9) | 19 (34.5) | 3 (60.0) | 7 (53.8) | 7 (53.8) | 3 (60.0) | 0 | 2 (50.0) | 75 (46.9) | 0.356 |
|
| |||||||||||
| Aztreonam | 6 (17.1) | 5 (18.5) | 7 (12.7) | 0 | 1 (7.7) | 2 (15.4) | 1 (20.0) | 1 (33.3) | 1 (25.0) | 24 (15.0) | 0.918 |
|
| |||||||||||
| Imipenem | 11 (31.4) | 4 (14.8) | 14 (25.5) | 0 | 4 (30.8) | 5 (38.5) | 0 | 1 (33.6) | 0 | 39 (24.4) | 0.373 |
|
| |||||||||||
| Amikacin | 15 (42.9) | 8 (29.6) | 23 (41.8) | 3 (60.0) | 7 (53.8) | 8 (61.5) | 2 (40.0) | 2 (66.7) | 2 (50.0) | 70 (43.8) | 0.674 |
| Gentamicin | 5 (14.3) | 4 (14.8) | 5 (9.1) | 0 | 0 | 4 (30.8) | 0 | 0 | 0 | 18 (11.3) | 0.288 |
|
| |||||||||||
| Norfloxacin | 5 (14.3) | 3 (11.1) | 1 (1.8) | 0 | 0 | 0 | 0 | 0 | 0 | 9 (5.6) | 0.229 |
| MDR | 18 (51.4) | 15 (55.6) | 25 (45.5) | 2 (40.0) | 8 (61.5) | 10 (76.9) | 1 (20.0) | 2 (66.7) | 2 (50.0) | 83 (51.9) | |
| Non MDR | 16 (45.7) | 12 (44.4) | 30 (54.5) | 3 (60.0) | 5 (58.5) | 3(23.1) | 4 (80.00) | 1 (33.3) | 2 (50.0) | 77 (38.1) | |
* There is no significant difference identified between antibiotic tested and phylogroups.
The correlation between the tested antimicrobial agents.
| AMP | AMC | SAM | TP | CXM | FOX | CTX | FEP | CRO | SXT | ATM | IPM | AL | CN | NOR | |
| AMP | 1 | ||||||||||||||
| AMC | .558 | 1 | |||||||||||||
| SAM | .374 | .475 | 1 | ||||||||||||
| TP | .309 | .388 | .444 | 1 | |||||||||||
| CXM | .226 | .309 | .323 | .335 | 1 | ||||||||||
| FOX | .232 | .291 | .473 | .335 | .312 | 1 | |||||||||
| CTX | .287 | .318 | .405 | .374 | .415 | .408 | 1 | ||||||||
| FEP | .188 | .259 | .234 | .387 | .386 | .225 | .319 | 1 | |||||||
| CRO | .285 | .394 | .343 | .566 | .582 | .314 | .509 | .582 | 1 | ||||||
| SXT | .332 | .378 | .401 | .356 | .226 | .338 | .222 | .326 | .290 | 1 | |||||
| ATM | .226 | .279 | .344 | .507 | .478 | .205 | .386 | .370 | .582 | .239 | 1 | ||||
| IPM | .236 | .315 | .414 | .476 | .334 | .397 | .224 | .348 | .369 | .465 | .332 | 1 | |||
| AK | 0.113 | 0.1 | 0.141 | .303 | 0.143 | 0.037 | 0.132 | .205 | .295 | .534 | .194 | .233 | 1 | ||
| CN | .192 | .167 | .344 | .386 | .206 | .337 | .192 | .326 | .290 | .743 | .404 | .443 | .164 | 1 | |
| NOR | .067 | .169 | .062 | -0.035 | .342 | .194 | .224 | 0.018 | .265 | .364 | .201 | -0.012 | .161 | 0.085 | 1 |
** Correlation is significant at the 0.01 level (2-tailed),
* Correlation is significant at the 0.05 level (2-tailed).
Hierarchical clustering for distribution of adhesion virulence genes among E. coli isolated from ASB cases, total (%).
| Cluster I | Cluster II | Cluster III | Cluster IV | Cluster V | Non clusterable | |
|---|---|---|---|---|---|---|
| 81 (50.6) | 11 (6.9) | 29 (18.1) | 10 (6.3) | 19 (11.9) | 10 (6.3) | |
|
| ||||||
|
| 81 (66.9) | 11 (9.1) | 0 | 10 (8.3) | 19 (15.7) | 0 |
|
| 0 | 0 | 0 | 10 (30.3) | 19 (51.5) | 6 (18.2) |
|
| 0 | 11 (40.7) | 0 | 10 (37.0) | 0 | 6 (18.5) |
|
| ||||||
| Group A | 21 (25.9) | 1 (9.10) | 6 (20.7) | 1 (10.0) | 4 (21.1) | 2 (20.0) |
| Group B1 | 20 (24.7) | 1 (9.1) | 3 (10.3) | 1 (10.0) | 2 (10.5) | 0 |
| Group B2 | 18 (22.2) | 8 (72.7) | 11 (37.9) | 8 (80.0) | 4 (21.4) | 6 (60.0) |
| Group C | 0 | 0 | 0 | 0 | 4 (21.1) | 1 (10.0) |
| Group D | 7 (8.6) | 0 | 3 (10.3) | 0 | 2 (10.5) | 1 (10.0) |
| Group E | 7 (8.6) | 1 (9.1) | 4 (13.8) | 0 | 1 (5.3) | 0 |
| Group F | 4 (4.9) | 0 | 0 | 0 | 1 (5.3) | 0 |
| Clade 1 | 2 (2.5) | 0 | 1 (3.4) | 0 | 0 | 0 |
| NT | 2 (2.5) | 0 | 1 (3.4) | 0 | 1 (5.30) | 0 |
Fig 1Hierarchical clustering of E. coli isolates according to the presence of adhesion functional virulence genes (fimH, papC and sfa).
Hierarchical clustering for distribution of iron acquisition virulence genes among E. coli isolated from ASB cases, total (%).
| Cluster I | Cluster II | Cluster III | Cluster IV | |
|---|---|---|---|---|
| 84 (52.5) | 25 (15.6) | 14 (8.8) | 37 (23.1) | |
|
| ||||
|
| 0 | 25 (64.1) | 14 (35.9) | 0 |
|
| 0 | 0 | 14 (27.5) | 37 (72.5) |
|
| ||||
| Group A | 23 (27.4) | 4 (16.0) | 1 (7.1) | 7 (18.9) |
| Group B1 | 21 (25.0) | 2 (8.0) | 3 (21.4) | 1 (2.7) |
| Group B2 | 17 (20.2) | 13 (52.0) | 10 (71.4) | 15 (40.5) |
| Group C | 3 (3.6) | 0 | 0 | 2 (5.4) |
| Group D | 7 (8.3) | 3 (12.0) | 0 | 3 (8.1) |
| Group E | 9 (10.7) | 1 (4.0) | 0 | 3 (8.1) |
| Group F | 2 (2.4) | 0 | 0 | 3 (8.1) |
| Clade 1 | 1 (1.2) | 1 (4.0) | 0 | 1 (2.7) |
| NT | 1 (1.2) | 1 (4.0) | 0 | 2 (5.4) |
Fig 2Hierarchical clustering of E. coli isolates according to the presence of iron uptake functional virulence genes (iroN and fyuA).
Hierarchical clustering for distribution of toxin virulence genes among E. coli isolated from ASB cases, total (%).
| Cluster I | Cluster II | Cluster III | Cluster IV | Cluster V | Nonclusterable | |
|---|---|---|---|---|---|---|
| 68 (42.5) | 14 (8.8) | 11 (6.90) | 23 (14.4) | 18 (11.3) | 26 (16.3) | |
|
| ||||||
|
| 0 | 0 | 0 | 0 | 18 (50.0) | 18 (50.0) |
|
| 0 | 14 (31.8) | 0 | 0 | 18 (40.9) | 12 (27.3) |
|
| 0 | 0 | 11 (91.7) | 0 | 0 | 1 (8.3) |
|
| 0 | 0 | 0 | 23 (41.8) | 18 (32.7) | 14 (25.5) |
|
| ||||||
| Group A | 20 (29.4) | 5 (35.7) | 4 (36.4) | 2 (8.7) | 1 (5.6) | 3 (11.5) |
| Group B1 | 17 (25.0) | 5 (35.7) | 0 | 1 (4.3) | 1 (5.6) | 3 (11.5) |
| Group B2 | 10 (14.7) | 3 (21.4) | 1 (9.1) | 12 (52.5) | 15 (83.3) | 14 (53.8) |
| Group C | 1 (1.5) | 1 (7.1) | 2 (18.2) | 1 (4.3) | 0 | 0 |
| Group D | 8 (11.8) | 0 | 1 (9.1) | 2 (8.7) | 0 | 2 (7.7) |
| Group E | 7 (10.3) | 0 | 2 (18.2) | 2 (8.7) | 1 (5.6) | 1 (3.8) |
| Group F | 2 (2.9) | 0 | 1 (9.1) | 1 (4.3) | 0 | 1 (3.8) |
| Clade 1 | 2 (2.9) | 0 | 0 | 0 | 0 | 1 (3.8) |
| NT | 1 (1.5) | 0 | 0 | 2 (8.7) | 0 | 1 (3.8) |
Fig 3Hierarchical clustering of E. coli isolates according to the presence of toxin functional virulence genes (cnf, sat, hlyA and usp).
Hierarchical clustering for distribution of capsule synthesis virulence genes among E. coli isolated from ASB cases, total (%).
| Cluster I | Cluster II | Cluster III | Cluster IV | |
|---|---|---|---|---|
| 84 (52.5) | 16 (10.0) | 8 (5.0) | 52 (32.5) | |
|
| ||||
| 0 | 0 | 8 (13.1) | 52 (85.2) | |
|
| 0 | 16 (66.7) | 8 (33.3) | 0 |
|
| ||||
| Group A | 27 (32.1) | 3 (18.8) | 0 | 5 (9.6) |
| Group B1 | 22 (26.2) | 3 (18.8) | 0 | 2 (3.8) |
| Group B2 | 18 (21.4) | 2 (12.5) | 5 (62.5) | 30 (57.7) |
| Group C | 2 (2.4) | 1 (6.3) | 0 | 2 (3.8) |
| Group D | 5 (6.0) | 3 (18.8) | 0 | 5 (9.6) |
| Group E | 6 (7.1) | 3 (18.8) | 2 (25.0) | 2 (3.8) |
| Group F | 1 (1.2) | 0 | 0 | 4 (7.7) |
| Clade 1 | 3 (3.6) | 0 | 0 | 0 |
| NT | 0 | 1 (6.3) | 1 (12.5) | 2 (3.8) |
Fig 4Hierarchical clustering of E. coli isolates according to the presence of capsule production functional virulence genes (kpsMTII and ompT).